Genetic Interactions of STAT3 and Anticancer Drug Development

Author： Fang Bingliang  

Publisher： MDPI

E-ISSN： 2072-6694|6|1|494-525

ISSN： 2072-6694

Source： Cancers, Vol.6, Iss.1, 2014-03, pp. : 494-525

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TRPV3 in Drug Development

By Broad Lisa M.   Mogg Adrian J.   Eberle Elizabeth   Tolley Marcia   Li Dominic L.   Knopp Kelly L.  

Pharmaceuticals, Vol. 9, Iss. 3, 2016-09 ,pp. : 55-55

MDPI

Access to resources Recommend Favorite

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

By Huang Tzu-Ting   Su Jung-Chen   Liu Chun-Yu   Shiau Chung-Wai   Chen Kuen-Feng  

International Journal of Molecular Sciences, Vol. 18, Iss. 6, 2017-06 ,pp. : 1234-1234

MDPI

Access to resources Recommend Favorite

Hsp90 Inhibitors and the Reduction of Anti-Cancer Drug Resistance by Non-Genetic and Genetic Mechanisms

By Lu Xiangyi   Wang Luan   Ruden Douglas M.  

Pharmaceuticals, Vol. 5, Iss. 9, 2012-08 ,pp. : 890-898

MDPI

Access to resources Recommend Favorite

STAT3 in Cancer—Friend or Foe?

By Zhang Hai-Feng   Lai Raymond  

Cancers, Vol. 6, Iss. 3, 2014-07 ,pp. : 1408-1440

MDPI

Access to resources Recommend Favorite

The Role of STAT3 in Thyroid Cancer

By Sosonkina Nadiya   Starenki Dmytro   Park Jong-In  

Cancers, Vol. 6, Iss. 1, 2014-03 ,pp. : 526-544

MDPI

Access to resources Recommend Favorite